Qualigen Historical Balance Sheet

QLGN Stock

USD 4.28 0.22 4.89%

Trend analysis of Qualigen Therapeutics balance sheet accounts such as Net Debt of 942.3 K, Accounts Payable of 2.3 M, Cash of 381.7 K or Non Current Assets Total of 823.2 K provides information on Qualigen Therapeutics' total assets, liabilities, and equity, which is the actual value of Qualigen Therapeutics to its prevalent stockholders. By breaking down trends over time using Qualigen Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Qualigen Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Qualigen Therapeutics is a good buy for the upcoming year.

Qualigen Therapeutics Inventory

1.12 Million

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Qualigen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.

About Qualigen Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Qualigen Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Qualigen Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Qualigen Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Qualigen currently owns. An asset can also be divided into two categories, current and non-current.

Qualigen Therapeutics Balance Sheet Chart

At this time, Qualigen Therapeutics' Total Liabilities is very stable compared to the past year. As of the 11th of December 2024, Property Plant And Equipment Gross is likely to grow to about 7.8 M, while Total Assets are likely to drop about 1.9 M.

Total Assets Other Current Liab Total Current Liabilities Accounts Payable

Add Fundamental

Total Assets

Total assets refers to the total amount of Qualigen Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Qualigen Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Qualigen Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Qualigen Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Qualigen Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Qualigen Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Qualigen Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Qualigen Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Qualigen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.At this time, Qualigen Therapeutics' Total Liabilities is very stable compared to the past year. As of the 11th of December 2024, Property Plant And Equipment Gross is likely to grow to about 7.8 M, while Total Assets are likely to drop about 1.9 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	3.3M	7.4M	614.6K	583.9K
Total Assets	22.8M	19.1M	2.0M	1.9M

Other Current Liab Total Assets

Qualigen Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment	Other Liab	Net Tangible Assets	Net Receivables
Total Assets		0.46	0.18	0.92	0.05	-0.89	0.22	-0.4	0.92	0.05	0.0	0.37	0.92	0.15	-0.36	-0.14	0.32	0.11	0.2	-0.28	0.97	-0.32	-0.19	-0.29	0.64	0.19
Other Current Liab	0.46		0.89	0.08	0.61	-0.08	-0.35	-0.41	0.13	0.63	-0.19	0.51	0.13	-0.34	0.12	0.53	0.77	0.48	0.89	0.13	0.29	0.3	0.29	0.18	0.62	-0.44
Total Current Liabilities	0.18	0.89		-0.21	0.56	0.19	-0.66	-0.03	-0.13	0.63	0.08	0.3	-0.13	-0.31	0.45	0.76	0.77	0.68	0.99	0.42	0.02	0.53	0.52	0.47	0.53	-0.71
Total Stockholder Equity	0.92	0.08	-0.21		-0.24	-0.98	0.48	-0.34	0.99	-0.27	0.0	0.2	0.99	0.28	-0.54	-0.45	-0.03	-0.18	-0.2	-0.47	0.97	-0.54	-0.42	-0.47	0.44	0.47
Property Plant And Equipment Net	0.05	0.61	0.56	-0.24		0.33	-0.31	-0.42	-0.28	0.74	-0.48	0.7	-0.28	-0.22	0.16	0.61	0.48	0.35	0.64	0.22	-0.14	0.62	0.6	-0.03	0.3	-0.14
Net Debt	-0.89	-0.08	0.19	-0.98	0.33		-0.5	0.27	-1.0	0.39	-0.02	-0.15	-1.0	-0.3	0.56	0.45	0.11	0.2	0.2	0.52	-0.97	0.55	0.46	0.47	-0.47	-0.45
Retained Earnings	0.22	-0.35	-0.66	0.48	-0.31	-0.5		-0.51	0.44	-0.52	-0.41	0.14	0.44	0.34	-0.95	-0.82	-0.61	-0.93	-0.69	-0.93	0.35	-0.61	-0.76	-0.88	-0.26	0.85
Accounts Payable	-0.4	-0.41	-0.03	-0.34	-0.42	0.27	-0.51		-0.28	-0.23	0.56	-0.43	-0.28	0.33	0.55	0.27	-0.15	0.37	-0.06	0.46	-0.33	0.28	0.35	0.5	-0.2	-0.34
Cash	0.92	0.13	-0.13	0.99	-0.28	-1.0	0.44	-0.28		-0.33	0.06	0.17	1.0	0.29	-0.52	-0.39	-0.04	-0.14	-0.14	-0.47	0.99	-0.52	-0.41	-0.44	0.51	0.4
Non Current Assets Total	0.05	0.63	0.63	-0.27	0.74	0.39	-0.52	-0.23	-0.33		-0.12	0.47	-0.33	-0.28	0.44	0.53	0.87	0.55	0.7	0.49	-0.2	0.48	0.53	0.42	0.03	-0.5
Non Currrent Assets Other	0.0	-0.19	0.08	0.0	-0.48	-0.02	-0.41	0.56	0.06	-0.12		-0.74	0.06	-0.08	0.51	0.07	0.15	0.39	0.06	0.49	0.03	-0.2	-0.04	0.55	0.07	-0.55
Other Assets	0.37	0.51	0.3	0.2	0.7	-0.15	0.14	-0.43	0.17	0.47	-0.74		0.17	0.36	-0.36	0.27	0.26	0.01	0.34	-0.32	0.25	0.47	0.38	-0.42	0.16	0.27
Cash And Short Term Investments	0.92	0.13	-0.13	0.99	-0.28	-1.0	0.44	-0.28	1.0	-0.33	0.06	0.17		0.29	-0.52	-0.39	-0.04	-0.14	-0.14	-0.47	0.99	-0.52	-0.41	-0.44	0.51	0.4
Common Stock Total Equity	0.15	-0.34	-0.31	0.28	-0.22	-0.3	0.34	0.33	0.29	-0.28	-0.08	0.36	0.29		-0.43	-0.12	-0.38	-0.27	-0.34	-0.45	0.21	0.19	0.1	-0.43	-0.32	0.39
Common Stock Shares Outstanding	-0.36	0.12	0.45	-0.54	0.16	0.56	-0.95	0.55	-0.52	0.44	0.51	-0.36	-0.52	-0.43		0.64	0.5	0.82	0.49	0.99	-0.46	0.45	0.62	0.93	0.1	-0.8
Capital Surpluse	-0.14	0.53	0.76	-0.45	0.61	0.45	-0.82	0.27	-0.39	0.53	0.07	0.27	-0.39	-0.12	0.64		0.48	0.81	0.77	0.61	-0.27	0.86	0.91	0.51	0.35	-0.7
Other Current Assets	0.32	0.77	0.77	-0.03	0.48	0.11	-0.61	-0.15	-0.04	0.87	0.15	0.26	-0.04	-0.38	0.5	0.48		0.69	0.82	0.54	0.09	0.26	0.37	0.58	0.31	-0.65
Other Stockholder Equity	0.11	0.48	0.68	-0.18	0.35	0.2	-0.93	0.37	-0.14	0.55	0.39	0.01	-0.14	-0.27	0.82	0.81	0.69		0.71	0.83	-0.03	0.52	0.74	0.76	0.46	-0.78
Total Liab	0.2	0.89	0.99	-0.2	0.64	0.2	-0.69	-0.06	-0.14	0.7	0.06	0.34	-0.14	-0.34	0.49	0.77	0.82	0.71		0.48	0.02	0.55	0.56	0.47	0.55	-0.69
Property Plant And Equipment Gross	-0.28	0.13	0.42	-0.47	0.22	0.52	-0.93	0.46	-0.47	0.49	0.49	-0.32	-0.47	-0.45	0.99	0.61	0.54	0.83	0.48		-0.4	0.42	0.61	0.9	0.12	-0.76
Total Current Assets	0.97	0.29	0.02	0.97	-0.14	-0.97	0.35	-0.33	0.99	-0.2	0.03	0.25	0.99	0.21	-0.46	-0.27	0.09	-0.03	0.02	-0.4		-0.43	-0.32	-0.39	0.62	0.31
Common Stock	-0.32	0.3	0.53	-0.54	0.62	0.55	-0.61	0.28	-0.52	0.48	-0.2	0.47	-0.52	0.19	0.45	0.86	0.26	0.52	0.55	0.42	-0.43		0.94	0.32	0.0	-0.43
Property Plant Equipment	-0.19	0.29	0.52	-0.42	0.6	0.46	-0.76	0.35	-0.41	0.53	-0.04	0.38	-0.41	0.1	0.62	0.91	0.37	0.74	0.56	0.61	-0.32	0.94		0.45	0.14	-0.51
Other Liab	-0.29	0.18	0.47	-0.47	-0.03	0.47	-0.88	0.5	-0.44	0.42	0.55	-0.42	-0.44	-0.43	0.93	0.51	0.58	0.76	0.47	0.9	-0.39	0.32	0.45		0.01	-0.87
Net Tangible Assets	0.64	0.62	0.53	0.44	0.3	-0.47	-0.26	-0.2	0.51	0.03	0.07	0.16	0.51	-0.32	0.1	0.35	0.31	0.46	0.55	0.12	0.62	0.0	0.14	0.01		-0.14
Net Receivables	0.19	-0.44	-0.71	0.47	-0.14	-0.45	0.85	-0.34	0.4	-0.5	-0.55	0.27	0.4	0.39	-0.8	-0.7	-0.65	-0.78	-0.69	-0.76	0.31	-0.43	-0.51	-0.87	-0.14

Click cells to compare fundamentals

Qualigen Therapeutics Account Relationship Matchups

Qualigen Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	3.7M	29.1M	22.8M	19.1M	2.0M	1.9M
Other Current Liab	2.2M	9.5M	3.3M	7.4M	614.6K	583.9K
Total Current Liabilities	5.3M	10.4M	4.6M	8.6M	4.1M	5.4M
Total Stockholder Equity	(1.9M)	18.3M	16.6M	7.2M	(2.1M)	(2.0M)
Property Plant And Equipment Net	1.7M	1.5M	696.1K	1.8M	1.8M	0.0
Net Debt	2.1M	(23.6M)	(15.9M)	(4.3M)	897.4K	942.3K
Retained Earnings	(47.3M)	(66.8M)	(84.7M)	(103.4M)	(116.8M)	(111.0M)
Accounts Payable	879.3K	500.8K	886.2K	619.6K	2.2M	2.3M
Cash	153.1K	24.0M	17.5M	7.0M	401.8K	381.7K
Non Current Assets Total	2.1M	902.1K	2.0M	8.3M	866.5K	823.2K
Non Currrent Assets Other	(2.1M)	18.3K	18.3K	24.0K	866.5K	909.8K
Other Assets	29.7K	18.3K	18.3K	24.0K	1.0	0.95
Cash And Short Term Investments	153.1K	24.0M	17.5M	7.0M	401.8K	381.7K
Common Stock Total Equity	49.4K	6.0K	19.1K	27.3	24.57	23.34
Common Stock Shares Outstanding	627K	723.7K	2.9M	3.8M	5.1M	5.3M
Liabilities And Stockholders Equity	3.7M	29.1M	22.8M	19.1M	2.0M	1.9M
Other Current Assets	98.4K	2.7M	1.4M	6.1M	765.0K	1.4M
Other Stockholder Equity	45.2M	85.1M	101.3M	110.5M	114.7M	81.5M
Total Liab	5.6M	10.8M	6.3M	10.3M	4.1M	5.9M
Property Plant And Equipment Gross	108.7K	678.12	5.2M	6.5M	7.4M	7.8M
Total Current Assets	1.6M	28.2M	20.8M	10.8M	1.2M	1.1M
Property Plant Equipment	1.5M	696.1K	1.8M	1.8M	2.0M	1.3M
Other Liab	2.7K	158.3K	92.9K	406.8K	467.8K	491.2K
Net Tangible Assets	(2.7M)	18.1M	16.4M	764.4K	879.1K	835.1K
Net Receivables	707.3K	615.8K	822.4K	538.6K	484.7K	588.3K
Inventory	660.1K	953.5K	1.1M	1.6M	1.8M	1.1M

Pair Trading with Qualigen Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Qualigen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Qualigen Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Qualigen Stock

0.73	VALN	Valneva SE ADR	Pair Corr
0.62	ERNA	Eterna Therapeutics	Pair Corr

Moving against Qualigen Stock

0.83	BMY	Bristol Myers Squibb	Pair Corr
0.81	GILD	Gilead Sciences	Pair Corr
0.65	ESPR	Esperion Therapeutics	Pair Corr
0.44	DYAI	Dyadic International	Pair Corr

The ability to find closely correlated positions to Qualigen Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Qualigen Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Qualigen Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Qualigen Therapeutics to buy it.

The correlation of Qualigen Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Qualigen Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Qualigen Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Qualigen Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Qualigen Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Qualigen Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Qualigen Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Qualigen Therapeutics Stock:

How To Invest In Qualigen

Details

Is Qualigen Stock a good investment?

Details

What is Qualigen Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.

You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Qualigen Therapeutics. If investors know Qualigen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Qualigen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

3.6 K

Revenue Per Share

1.034

Quarterly Revenue Growth

0.137

Return On Assets

(0.75)

Return On Equity

(8.42)

The market value of Qualigen Therapeutics is measured differently than its book value, which is the value of Qualigen that is recorded on the company's balance sheet. Investors also form their own opinion of Qualigen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Qualigen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Qualigen Therapeutics' market value can be influenced by many factors that don't directly affect Qualigen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Qualigen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Qualigen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Qualigen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Qualigen Historical Balance Sheet

Qualigen Therapeutics Inventory

1.12 Million

About Qualigen Balance Sheet Analysis

Qualigen Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Qualigen Therapeutics balance sheet Correlations

Qualigen Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Qualigen Therapeutics balance sheet Accounts

Pair Trading with Qualigen Therapeutics

Moving together with Qualigen Stock

Moving against Qualigen Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 0.99	Total Current Liabilities
Cash	+ 0.99	Total Stockholder Equity
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 0.98	Total Stockholder Equity
Total Current Assets	- 0.97	Net Debt
Common Stock Shares Outstanding	- 0.95	Retained Earnings
Property Plant And Equipment Gross	- 0.93	Retained Earnings